The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy

Menopause is associated with health concerns including vasomotor symptoms, vulvar/vaginal atrophy (VVA), and osteoporosis. Estrogen therapy or combined estrogen-progestin therapy (EPT) are primary treatment options for menopausal symptom relief and osteoporosis prevention. Because EPT has been associated with some safety/tolerability concerns relating to undesirable effects of estrogen and progestin, alternative options are needed. The tissue selective estrogen complex (TSEC) is a novel class of agents pairing a selective estrogen receptor modulator (SERM) with 1 or more estrogens. The TSEC combines the established efficacy of estrogens on menopausal symptoms and bone with the protective effects of a SERM on the reproductive tract. The pairing of bazedoxifene (BZA) with conjugated estrogens (CE) has been evaluated in a series of phase 3 clinical trials. BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg have shown efficacy in reducing the frequency and severity of hot flushes, relieving VVA symptoms, and maintaining bone mass while protecting the endometrium and breast. These BZA/CE doses have been associated with a favorable safety/tolerability profile, with higher rates of cumulative amenorrhea and lower incidences of breast pain than those reported for EPT. Thus, BZA/CE may be a promising alternative to conventional EPT for treating non-hysterectomized, postmenopausal women.

[1]  A. Chines,et al.  Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women , 2013, Climacteric : the journal of the International Menopause Society.

[2]  B. Edwards,et al.  Endocrinology of menopause. , 2013, Periodontology 2000.

[3]  A. Chines,et al.  137 EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS ON SLEEP PARAMETERS AND HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN , 2012 .

[4]  Peter J. Schmidt,et al.  The 2022 hormone therapy position statement of The North American Menopause Society , 2022, Menopause.

[5]  A. Chines,et al.  67 SAFETY AND TOLERABILITY OF BAZEDOXIFENE/CONJUGATED ESTROGENS IN POSTMENOPAUSAL WOMEN: FINDINGS FROM A 1 -YEAR, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED, PHASE 3 TRIAL , 2012 .

[6]  A. Chines,et al.  68 THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS ON BREAST DENSITY IN POSTMENOPAUSAL WOMEN , 2012 .

[7]  J. Manson,et al.  Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials , 2012, Breast Cancer Research and Treatment.

[8]  OBGYN.net Staff.  Fast Facts on Osteoporosis , 2011 .

[9]  B. Komm,et al.  Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. , 2011, Bone.

[10]  C. Weaver,et al.  The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010) , 2011, Menopause.

[11]  J. Levine.  Treating menopausal symptoms with a tissue-selective estrogen complex. , 2011, Gender medicine.

[12]  E. Ridgway.  Endocrine Reviews: Can We Make a Better Best? , 2011 .

[13]  Y. Cheung,et al.  Factors that influence changes in mammographic density with postmenopausal hormone therapy. , 2010, Taiwanese journal of obstetrics & gynecology.

[14]  R. Preston,et al.  Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. , 2010, Fertility and sterility.

[15]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[16]  Mark A Helvie,et al.  Mammographic breast density: effect on imaging and breast cancer risk. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  Jacques P. Brown,et al.  Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis , 2010, BMC musculoskeletal disorders.

[18]  R. Kagan,et al.  A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women , 2010, Menopause.

[19]  G. Bachmann,et al.  Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy , 2010, Climacteric : the journal of the International Menopause Society.

[20]  J. Manson,et al.  Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society , 2006, Menopause.

[21]  G. Constantine,et al.  Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial , 2009, Menopause.

[22]  A. Chines,et al.  Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women , 2009, Menopause.

[23]  E. Trott,et al.  The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis , 2009, Menopause.

[24]  A. Chines,et al.  Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis , 2009, Menopause.

[25]  V. Lewis.  Undertreatment of menopausal symptoms and novel options for comprehensive management , 2009, Current medical research and opinion.

[26]  G. Constantine,et al.  Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. , 2009, Fertility and sterility.

[27]  G. Bachmann,et al.  Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. , 2009, Fertility and sterility.

[28]  R. Lindsay,et al.  Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. , 2009, Fertility and sterility.

[29]  V. Lewis,et al.  Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. , 2009, Fertility and sterility.

[30]  W. Utian,et al.  Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. , 2009, Maturitas.

[31]  G. Bachmann,et al.  Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally , 2009, Menopause.

[32]  B. Komm,et al.  Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. , 2009, Endocrinology.

[33]  E. Capp,et al.  Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial. , 2009, Maturitas.

[34]  B. Komm.  Review Article: A New Approach to Menopausal Therapy: The Tissue Selective Estrogen Complex , 2008, Reproductive Sciences.

[35]  B. Komm,et al.  The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. , 2008, Endocrinology.

[36]  Claus Christiansen,et al.  Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  J. Manson,et al.  Estrogen therapy and coronary-artery calcification. , 2007, The New England journal of medicine.

[38]  J. Kanpittaya,et al.  Effect of estrogen-progestin and estrogen on mammographic density. , 2007, Journal of reproductive medicine.

[39]  G. Bachmann,et al.  The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society , 2007, Menopause.

[40]  Y. Qu,et al.  The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety , 2007, Menopause.

[41]  J. Manson,et al.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. , 2007, JAMA.

[42]  S. Carranza-Lira,et al.  Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. , 2007, International journal of fertility and women's medicine.

[43]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2007, Breast Cancer Research and Treatment.

[44]  D. C. Knight,et al.  Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. , 2006, Maturitas.

[45]  G. Anderson,et al.  Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. , 2006, Maturitas.

[46]  G. Ursin,et al.  Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy. , 2006, Archives of internal medicine.

[47]  Jennifer G. Robinson,et al.  Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. , 2006, American heart journal.

[48]  V. McCormack,et al.  Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[49]  A. LaCroix,et al.  Effects of Conjugated Equine Estrogen on Risk of Fractures and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  U. Topal,et al.  Effects of hormone replacement therapy regimens on mammographic breast density: The role of progestins , 2006, The journal of obstetrics and gynaecology research.

[51]  J. Simon,et al.  Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 μg) in women with postmenopausal symptoms: Updated analysis of three randomized, controlled trials , 2006 .

[52]  J. Buring,et al.  Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative , 2006, Circulation.

[53]  Rongwei Fu,et al.  Management of Miscarriage: Expectant, Medical, or Surgical? Results of Randomised Controlled Trial (Miscarriage Treatment [MIST] Trial) , 2006, Annals of internal medicine.

[54]  Garnet L Anderson,et al.  Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. , 2006, JAMA.

[55]  R. Langer,et al.  Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus , 2006, Archives of internal medicine.

[56]  A. Paterson,et al.  Mammographic breast density as an intermediate phenotype for breast cancer. , 2005, The Lancet. Oncology.

[57]  A. LaCroix,et al.  Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. , 2005, Archives of internal medicine.

[58]  B. Komm,et al.  Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. , 2005, Endocrinology.

[59]  W. Utian.  Health and Quality of Life Outcomes , 2005 .

[60]  A. Genazzani,et al.  Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17β-estradiol and trimegestone versus two regimens containing 1 or 2 mg 17β-estradiol and norethisterone acetate , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[61]  B. Pornel,et al.  A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a 2-year period , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[62]  R. Santen.  Menopausal hormone therapies: Their effect on mammographic density and breast cancer risk , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[63]  Susan R. Johnson,et al.  Menopausal Symptoms and Treatment-Related Effects of Estrogen and Progestin in the Women's Health Initiative , 2005, Obstetrics and gynecology.

[64]  A. Maclennan,et al.  Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. , 2004, The Cochrane database of systematic reviews.

[65]  R. Prentice,et al.  Estrogen plus progestin and risk of venous thrombosis. , 2004, JAMA.

[66]  N. Benda,et al.  Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens , 2004, Climacteric : the journal of the International Menopause Society.

[67]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[68]  S. Davis,et al.  Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium—a pilot study , 2004, Menopause.

[69]  G. B. Lopes,et al.  Effects of estrogen plus progestin on health-related quality of life. , 2004, The New England journal of medicine.

[70]  S. Chichareon,et al.  Compliance with hormone replacement therapy at Songklanagarind Hospital , 2003, The journal of obstetrics and gynaecology research.

[71]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[72]  C. Kooperberg,et al.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. , 2003, JAMA.

[73]  J. Manonai,et al.  Compliance with hormone replacement therapy in Thai women. , 2003, Maturitas.

[74]  C. Lam,et al.  A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women. , 2003, Maturitas.

[75]  S. Siddhanti,et al.  Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women , 2003, Menopause.

[76]  M. Gelfand,et al.  Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study , 2003, Menopause.

[77]  J. Cauley,et al.  Menopausal Symptoms in Older Women and the Effects of Treatment With Hormone Therapy , 2002, Obstetrics and gynecology.

[78]  G. Guyatt,et al.  V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women , 2002 .

[79]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[80]  R. Lindsay,et al.  Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. , 2002, JAMA.

[81]  E. Vittinghoff,et al.  Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. , 2002, JAMA.

[82]  B. Komm,et al.  Developing a SERM: Stringent Preclinical Selection Criteria Leading to an Acceptable Candidate (WAY‐140424) for Clinical Evaluation , 2001, Annals of the New York Academy of Sciences.

[83]  D. Torgerson,et al.  Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. , 2001, JAMA.

[84]  D. Schneider,et al.  Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. , 2001, Fertility and sterility.

[85]  G. Bachmann,et al.  Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. , 2001, Fertility and sterility.

[86]  H. Burger,et al.  A Prospective Population‐Based Study of Menopausal Symptoms , 2000, Obstetrics and gynecology.

[87]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[88]  I Persson,et al.  Risk of endometrial cancer following estrogen replacement with and without progestins. , 1999, Journal of the National Cancer Institute.

[89]  Susan R. Johnson,et al.  Symptom Relief and Side Effects of Postmenopausal Hormones: Results From the Postmenopausal Estrogen/Progestin Interventions Trial , 1998, Obstetrics and gynecology.

[90]  D. McClish,et al.  META‐ANALYSIS OF ESTROGEN THERAPY IN THE MANAGEMENT OF UROGENITAL ATROPHY IN POSTMENOPAUSAL WOMEN: SECOND REPORT OF THE HORMONES AND UROGENITAL THERAPY COMMITTEE , 1998, Obstetrics and gynecology.

[91]  P. Polo-Kantola,et al.  When does estrogen replacement therapy improve sleep quality? , 1998, American journal of obstetrics and gynecology.

[92]  B. L. Riggs,et al.  A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[93]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[94]  D. Archer,et al.  Bleeding Patterns in Postmenopausal Women Taking Continuous Combined or Sequential Regimens of Conjugated Estrogens With Medroxyprogesterone Acetate , 1994, Obstetrics and gynecology.

[95]  H. Ziel,et al.  Increased risk of endometrial carcinoma among users of conjugated estrogens. , 1975, The New England journal of medicine.

[96]  D. Thompson,et al.  Association of exogenous estrogen and endometrial carcinoma. , 1975, The New England journal of medicine.

[97]  L. Shulman.  Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy: A Randomized Controlled Trial , 2011 .

[98]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2008 .

[99]  Lin Shou-qin,et al.  The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women:2007 position statement of The North American Menopause Society , 2008 .

[100]  J. Michael.  Textbook of Medical Physiology , 2005 .

[101]  D. Archer,et al.  Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. , 2003, Menopause.

[102]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. , 2002, Endocrine reviews.

[103]  D. McDonnell,et al.  Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. , 2002, Recent progress in hormone research.

[104]  H. Burger,et al.  Hormonal changes in the menopause transition. , 2002, Recent progress in hormone research.

[105]  G. Guyatt,et al.  Meta-Analyses of Therapies for Postmenopausal Osteoporosis , 2002 .

[106]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .